SW-BIC-213 / Stemirna Therap - LARVOL DELTA

Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). (PubMed, EClinicalMedicine) - P3 | "A heterologous booster with the COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and proves highly immunogenic and efficacious in preventing symptomatic COVID-19 in individuals who have previously received two doses of inactivated vaccine. Shanghai Strategic Emerging Industries Development Special Fund, Biomedical Technology Support Special Project of Shanghai "Science and Technology Innovation Action Plan", Shanghai Municipal Science and Technology Commission."

Clinical • Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 (clinicaltrials.gov) - P2/3 | N=800 | Not yet recruiting | Sponsor: Stemirna Therapeutics

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial. (PubMed, EBioMedicine) - "SW-BIC-213, a core-shell structured lipopolyplex (LPP) based mRNA vaccine, was safe, tolerable, and immunogenic as a heterologous booster in healthy Chinese adults."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

New Generation mRNA Booster Vaccine Against Emerging VOCs (clinicaltrials.gov) - P3 | N=2000 | Recruiting | Sponsor: Stemirna Therapeutics | Trial primary completion date: Dec 2022 ➔ May 2023

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs (clinicaltrials.gov) - P3 | N=600 | Active, not recruiting | Sponsor: Stemirna Therapeutics

New P3 trial • Infectious Disease • Novel Coronavirus Disease

New Generation mRNA Booster Vaccine Against Emerging VOCs (clinicaltrials.gov) - P3 | N=2000 | Recruiting | Sponsor: Stemirna Therapeutics

New P3 trial • Infectious Disease • Novel Coronavirus Disease